Preferences for oral anticoagulant treatment in the medium and long term prevention of stroke in non valvular atrial fibrillation;Preferencias por los tratamientos anticoagulantes orales para la prevención a medio y largo plazo del ictus en la fibrilación auricular no valvular

Revista de Neurologia

Volumn 55, Issue 1, 2012, Pages 11-19

  González Rojas, Nuria ^a   Giménez, Emmanuel ^a   Angeles Fernandez M ^b   Heineger, Ana I ^c   Martínez, José L ^d   López, Julia Villar ^e   Lizán, Luis ^e  

^a Health Economics and Outcomes Research   (Spain)

^b AVAC   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d Delegación de Salud de Málaga   (Spain)

^e UNIVERSITAT JAUME I   (Spain)

Author keywords

Oral anticoagulants; Patients' preferences; Stroke prevention

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; BRAIN HEMORRHAGE; DIET; DRUG COST; DRUG EFFICACY; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATIENT ATTITUDE; PROPHYLAXIS; REVIEW; SEMI STRUCTURED INTERVIEW; STROKE;

EID: 84863806961     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5501.2011580     Document Type: Review

References (36)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010; 121: 948-54.
2. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology. Eur Heart J 2010; 31: 2369-429.
3. Ghatnekar O, Glader E. The effect of atrial fibrillation on stroke-related inpatient cost in Sweden: a 3-year analysis of registry incidence data from 2001. Value Health 2008; 11: 862-8.
4. Steger C, Pratter A, Martinek-Bregel M, Avanzini M, Valentin A, Slany J, et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry. Eur Heart J 2004; 25: 1734-40.
5. Heras M, Fernández A, Gómez JA, Iriarte JA, Lidón RM, Pérez F, et al. Guías de práctica clínica de la Sociedad Española de Cardiología sobre el uso de antiagregantes y anticoagulantes en cardiología. Rev Esp Cardiol 1999; 52: 801-20.
6. Penning-Van Beest FJA, Van Meegen E, Rosendaal FR, Stricker BHC. Characteristics of anticoagulant therapy and comorbidity related to overcoagulation. Thromb Haemost 2001; 86: 569-74.
7. Hirsh J, Dalen JE, Deykin F, Poller L, Bussey H. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995; 108 (Suppl): S231-S246.
8. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
9. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; the RE-LY Steering Committee and Investigators. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 1875-6.
10. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
11. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
12. Howitt A, Armstrong D. Implementing evidence based medicine in general practice: audit. An qualitative study of antithrombotic treatment for atrial fibrillation. BMJ 1999; 318: 1324-7.
13. Thomson R, Partin D, Eccles M, Sudlow M, Robinson A. Decision analysis and guidelines for anticoagulation therapy to prevent stroke in patients with atrial fibrillation. Lancet 2000; 355: 956-962. [erratum in Lancet 2000; 355: 1466].
14. Protheroe J, Fahey T, Montgomery AA, Peters TJ. The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient-based decision analysis. BMJ 2000; 320: 1380-4.
15. Picón-Prado E. Una comparación Monte Carlo de tres métodos métricos de segmentación con análisis conjunto. Psicológica 2004; 25: 231-52.
16. North E, De Vos R. The use of conjoint analysis to determine consumer buying preferences: a literature review. Journal of Family Ecology and Consumer Sciences 2002; 30: 32-9.
17. González-Rojas N, Lizán L, Paz S. Preferencias de los pacientes con fibrilación auricular por los anticoagulantes orales para la profilaxis del ictus: resultados preliminares [poster 35]. XXX Jornadas de Economía de la Salud 'Servicios sanitarios: ¿cuáles?, ¿para quién?, ¿cómo?'. Gac Sanit 2010; 24: 1-108.
18. Schwarz G. Estimating the dimension of a model. Ann Stat 1978; 6: 461-4.
19. Bogdan M, Ghosh JK, Doerge RW. Modifying the Schwarz Bayesian Information Criterion to locate multiple interacting quantitative trait loci. Genetics 2004; 167: 989-99.
20. Fleischman Foreit KG, Foreit JR. Willingness to pay surveys for setting prices in for reproductive health products and services. A user's manual. Washington DC: United States Agency for International Development; 2004.
21. Ryan M. Using willingness to pay to assess the benefits of assisted reproductive techniques. Health Econ 1996; 5: 543-58.
22. Johnson FR, Özdemir S, Mansfield C, Hass S, Miller DW, Siegel CA, et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007; 133: 769-79.
23. Palumbo A, De la Fuente P, Rodríguez M, Sánchez F, Martínez-Salazar J, Muñoz M, et al. Willingness to pay and conjoint analysis to determine women's preferences for ovarian stimulating hormones in the treatment of infertility in Spain. Hum Reprod 2011; 26: 1790-8.
24. Doyle S, Lloyd A, Walker M. Health state utility scores in advanced non-small cell lung cancer. Lung Cancer 2008; 62: 374-80.
25. Devereaux PJ, Anderson DR, Gardner MJ, Putnam W, Flowerdew GJ, Brownell BF, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 2001; 323: 1-7.
26. Edwards A, Elwyn G, Mulley A. Explaining risks: turning numerical data into meaningful pictures. BMJ 2002; 324: 827-30.
27. Pettinger-Waclawiw MA, Davis KB, Thomason T, Garg R, Griffin B, Egan DA. Compliance to multiple interventions in a high risk population. Ann Epidemiol 1999; 9: 408-18.
28. Hixson-Wallace JA, Dotson JB, Blakey SA. Effect of regimen complexity on patient satisfaction and compliance with warfarin therapy. Clin Appl Thrombosis/Hemostasis 2001; 7: 33-7.
29. Say RE, Thomson R. The importance of patient preferences in treatment decisions-challenges for doctors. BMJ 2003; 327: 542-5.
30. Smith MB, Christensen N, Wang S, Strohecker J, Day JD, Weiss JP, et al. Warfarin knowledge in patients with atrial fibrillation: implications for safety, efficacy and education strategies. Cardiology 2010; 116: 61-9.
31. Rohrer JE, Takahashi PY, Adamson SC. Age, obesity, and medical visits in family medicine. Popul Health Manag 2008; 11: 255-9.
32. Cookson R. Willingness to pay methods in health care: a skeptical view. Health Econ 2003; 12: 891-4.
33. Seculi E, Fusté J, Brugulat P, Juncá S, Rue M, Guillén M. Percepción del estado de salud en varones y mujeres en las últimas etapas de la vida. Gac Sanit 2001; 15: 217-23.
34. Kleinman L, McIntosh E, Ryan M, Schmier J, Crawley J, Locke GR, et al. Willingness to pay for complete symptom relief of gastroesophageal reflux disease. Arch Intern Med 2002; 162: 1361-6.
35. Masjuán J. Controversia. Dabigatrán en el tratamiento preventivo del ictus embólico: a favor de su utilización como fármaco de primera línea. Rev Neurol 2012; 54: 257-9.
36. Calleja-Puerta S. Controversia. Dabigatrán en el tratamiento preventivo del ictus embólico: en contra de su utilización como fármaco de primera línea. Rev Neurol 2012; 54: 260-2.